Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CompumedicsASX:CMP -2.17%51 Future 3-5Y EPS without NRI Growth Rate is 266.18 as of Sep. 12, 2026. GuruFocus rates ASX:CMP with a GF Score™ of 51/100 and a GF Value™ of A$0.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 284 Medical Devices & Instruments companies, Compumedics ranks better than 99.65% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Compumedics's Future 3-5Y EPS without NRI Growth Rate is 266.18.
Compumedics (ASX:CMP) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Compumedics Future 3-5Y EPS without NRI Growth Rate Related Terms
ASX:CMP vs ABT, SYK, MDT: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Compumedics's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compumedics Future 3-5Y EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Compumedics's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 266.18 mean?
Compumedics (ASX:CMP) has a Future 3-5Y EPS without NRI Growth Rate of 266.18 as of Sep. 12, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Compumedics and its competitors. According to the industry distribution chart, Compumedics ranks #1 out of 284 companies in the Medical Devices & Instruments industry, placing it in the top 0.40000000000001%.
Is Compumedics' Future 3-5Y EPS without NRI Growth Rate too high?
Compumedics' current Future 3-5Y EPS without NRI Growth Rate is 266.18. The Medical Devices & Instruments industry median Future 3-5Y EPS without NRI Growth Rate is 20.78. Compumedics' value of 266.18 is 1181.3% above this industry median. Based on the distribution chart, Compumedics ranks #1 out of 284 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Compumedics has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Compumedics' Future 3-5Y EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Compumedics ranks #1 out of 284 companies for Future 3-5Y EPS without NRI Growth Rate. This places Compumedics in the top 0% of its industry — outperforming the majority of peers. The industry median Future 3-5Y EPS without NRI Growth Rate is 20.78. Compumedics' value of 266.18 is 1181.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median Future 3-5Y EPS without NRI Growth Rate among Medical Devices & Instruments companies is 20.78, based on 284 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compumedics's current Future 3-5Y EPS without NRI Growth Rate of 266.18 is 1181.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Compumedics and its competitors. For the Medical Devices & Instruments industry, the median Future 3-5Y EPS without NRI Growth Rate is 20.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compumedics's current Future 3-5Y EPS without NRI Growth Rate is 266.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.31, compared to a current price of A$0.23 — trading 27.4% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 266.18 and 1181.3% above the Medical Devices & Instruments industry median of 20.78. Compumedics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current Future 3-5Y EPS without NRI Growth Rate is 266.18 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compumedics (ASX:CMP) Overvalued in 2026?
Based on GuruFocus' analysis, Compumedics stock appears to be undervalued.
The current stock price of A$0.23 is trading 27.4% below its estimated GF Value™ of A$0.31.
GuruFocus considers Compumedics to be Modestly Undervalued.
Key valuation signals for ASX:CMP:
Future 3-5Y EPS without NRI Growth Rate: 266.18
GF Value™: A$0.31 vs. price of A$0.23 (27.4% below fair value)
Industry Position: 1181.3% above the Medical Devices & Instruments median (#1 of 284)
No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
51GF Score
Get the complete analysis for ASX:CMP
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMP has been successfully added to your 
